Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    5-Methoxy-2-Aminoindane

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Scisparc, Clearmind Medicine Partner For Depression Therapy
    Scisparc, Clearmind Medicine Partner For Depression Therapy

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256253/0/en/SciSparc-NeuroThera-Labs-Clearmind-Medicine-Collaboration-Leads-to-Patent-Application-for-Depression-Therapy.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    NeuroThera Labs, Clearmind Announce Weight Loss Patent
    NeuroThera Labs, Clearmind Announce Weight Loss Patent

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254524/0/en/SciSparc-NeuroThera-Labs-Announces-Publication-of-International-Patent-in-Collaboration-with-Clearmind-Medicine-for-Novel-Therapy-Targeting-Weight-Loss-and-Fatty-Liver-Disease.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share
    Clearmind Medicine's MEAI Spotlighted in Prestigious Review
    Clearmind Medicine's MEAI Spotlighted in Prestigious Review

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/12/3204638/0/en/Clearmind-Medicine-s-MEAI-Spotlighted-in-Prestigious-Review-Leading-Experts-Affirm-Transformative-Potential-for-Alcohol-Use-Disorder-Treatment.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Neurothera, Clearmind Secure Patent for Novel Depression Therapy
    Neurothera, Clearmind Secure Patent for Novel Depression Therapy

    20 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/20/3191728/0/en/SciSparc-Neurothera-Labs-Announces-Israeli-Patent-Application-in-Collaboration-with-Clearmind-Medicine-for-Novel-Non-Hallucinogenic-Neuroplastogen-Treatment-for-Depression.html

    GLOBENEWSWIRE
    20 Nov 2025
    Share Share
    Clearmind Files Patent for Non-Hallucinogenic Psychedelic Drug
    Clearmind Files Patent for Non-Hallucinogenic Psychedelic Drug

    17 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/17/3189045/0/en/Clearmind-Medicine-Files-Israeli-Patent-for-Novel-Non-Hallucinogenic-Neuroplastogen-Treatment-for-Depression.html

    GLOBENEWSWIRE
    17 Nov 2025
    Share Share
    Clearmind Enhances MEAI Depression Treatment IP Protection
    Clearmind Enhances MEAI Depression Treatment IP Protection

    05 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181244/0/en/Clearmind-Expands-Global-IP-Protection-for-MEAI-in-Depression-Treatment-with-New-South-Korea-Patent-Filing.html

    GLOBENEWSWIRE
    05 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.